Group 1 - The stock price of Jinling Pharmaceutical reached 7.28 yuan as of the close on August 22, 2025, with an increase of 0.02 yuan, representing a rise of 0.28% compared to the previous trading day [1] - The trading volume on that day was 171,300 hands, with a total transaction amount of 125 million yuan [1] - Jinling Pharmaceutical is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, chemical raw materials, and formulations, covering multiple therapeutic areas including cardiovascular, anti-tumor, and digestive systems [1] Group 2 - As of August 20, 2025, the total number of shareholders for Jinling Pharmaceutical was 37,622 [1] - On August 22, the net inflow of main funds was 6.3088 million yuan, with a cumulative net inflow of 18.0238 million yuan over the past five days [1]

证券日报网讯金陵药业（000919）8月22日在互动平台回答投资者提问时表示，截至2025年8月20日公司 股东人数为37622户。 ...

Group 1 - The high-pressure oxygen chamber concept sector experienced a decline of 0.76%, ranking among the top declines in concept sectors as of the market close on August 22 [1] - Within the sector, major declines were observed in companies such as Samsung Medical, Aoyang Health, and Dahu Co., with notable increases in Hangyang Co., Yinkang Life, and International Medicine, which rose by 0.97%, 0.86%, and 0.37% respectively [1] Group 2 - The high-pressure oxygen chamber concept sector saw a net outflow of 260 million yuan in principal funds today, with six stocks experiencing net outflows [2] - The stock with the highest net outflow was Tiedao Heavy Industry, which had a net outflow of 143 million yuan, followed by Innovative Medical, Samsung Medical, and Aoyang Health with net outflows of 60.83 million yuan, 43.65 million yuan, and 13.12 million yuan respectively [2] - Conversely, the stocks with the highest net inflows included International Medicine, Jinling Pharmaceutical, and Yinkang Life, with net inflows of 3.35 million yuan, 3.27 million yuan, and 3.20 million yuan respectively [2]

Core Viewpoint - Jinling Pharmaceutical Co., Ltd. has received a drug re-registration approval notice for its Hydrolyzed Protein Injection, which will facilitate the resumption of production and sales of this product [1][3]. Group 1: Drug Registration Details - The drug in question is Hydrolyzed Protein Injection, which is a sterilized solution of hydrolyzed casein and whey protein with sorbitol, primarily used for severe amino acid deficiency due to major surgical trauma, extensive burns, and various diseases causing hypoproteinemia [2]. - The application for re-registration was accepted under the number CYHZ2514512, and the approval was granted by the Fujian Provincial Drug Administration [1]. Group 2: Impact on the Company - The approval for the re-registration of the drug will benefit the company by allowing the resumption of normal production and sales; however, it is not expected to have a significant impact on the company's recent operating performance [3]. - The company is required to conduct subsequent work in strict accordance with regulatory requirements to achieve market sales of the product [3].

Policy Developments - The National Healthcare Security Administration issued the "Guidelines for the Establishment of Pricing Projects for Physical Therapy Medical Services (Trial)" which integrates existing pricing projects into 32 items, with 7 additional charges and 1 expansion item [2] Medical Device Approvals - In July, the National Medical Products Administration approved 295 medical device products, including 240 domestic Class III devices, 21 imported Class III devices, 29 imported Class II devices, and 5 devices from Hong Kong, Macau, and Taiwan [4] Company Announcements - New Industries announced that 18 of its chemiluminescent reagent products received IVDR CE certification, allowing them to enter the EU market, which is expected to enhance the company's competitiveness [5] - Jining Pharmaceutical received a drug re-registration approval for hydrolyzed protein injection, which is used for severe amino acid deficiency and will help restore normal production and sales [6] - Chongqing Pharmaceutical Holdings reported a net profit of 282 million yuan for the first half of the year, with a revenue of 41.188 billion yuan, marking a 3.54% year-on-year increase [8] - Jimin Health reported a net loss of 52.6959 million yuan for the first half of 2025, with a revenue of 36.6 million yuan, down 21.30% year-on-year [9] - Chenguang Bio announced plans to transfer 97.5% of its subsidiary Chenguang Tianrun Pharmaceutical to Sichuan Tongsheng Biomedical, with the transfer based on the subsidiary's equity as of July 31, 2025 [11] - Baiyang Pharmaceutical's controlling shareholder plans to increase capital and change the shareholding structure, with a new entity set to acquire 80% of the controlling group [13] Industry Events - A groundbreaking cervical spine surgery was successfully performed in Shanghai, utilizing innovative "satellite steel plate" technology to stabilize a severely injured patient's spine [15] - Guangxi plans to provide free HPV vaccinations to nearly 960,000 eligible girls from 2025 to 2027, emphasizing the importance of preventive healthcare [16] Shareholder Actions - Multiple shareholders of Sanxin Medical plan to reduce their stakes in the company due to personal financial needs, with specific share amounts outlined for each individual [18]

证券日报网讯8月20日晚间，金陵药业（000919）发布公告称，公司分公司金陵药业股份有限公司福州 梅峰制药厂于近日收到福建省药品监督管理局下发的药品再注册批准通知书。 ...

Core Viewpoint - Jinling Pharmaceutical (000919.SZ) has received a drug re-registration approval notice from the Fujian Provincial Drug Administration for its hydrolyzed protein injection, indicating a positive regulatory development for the company [1] Company Summary - Jinling Pharmaceutical's subsidiary, Fuzhou Meifeng Pharmaceutical Factory, has been granted approval for the hydrolyzed protein injection, which is a sterilized solution of hydrolyzed casein and whey protein with sorbitol [1] - The hydrolyzed protein injection is primarily used for severe amino acid deficiency caused by serious surgical trauma and extensive burns, as well as for hypoproteinemia resulting from various diseases [1]

Core Viewpoint - Jinling Pharmaceutical (000919.SZ) has received a drug re-registration approval notice for hydrolyzed protein injection from the Fujian Provincial Drug Administration, indicating a significant regulatory milestone for the company [1] Group 1: Company Developments - Jinling Pharmaceutical's subsidiary, Fuzhou Meifeng Pharmaceutical Factory, has been granted approval for hydrolyzed protein injection, which is a sterilized solution of hydrolyzed casein and whey protein with sorbitol [1] - The hydrolyzed protein injection is primarily used for severe amino acid deficiency caused by major surgical trauma, extensive burns, and various diseases leading to hypoproteinemia [1]

Group 1 - The high-pressure oxygen chamber concept declined by 0.68%, ranking among the top declines in concept sectors as of the market close on August 20 [1] - Within the high-pressure oxygen chamber sector, companies such as Innovate Medical, Yinkang Life, and Aoyang Health experienced significant declines, while Iron Construction Heavy Industry, Samsung Medical, and Dahu Co. saw increases of 4.29%, 1.08%, and 0.89% respectively [1] - The high-pressure oxygen chamber sector experienced a net outflow of 444 million yuan in main funds, with Innovate Medical leading the outflow at 537 million yuan [2] Group 2 - The top gainers in the market included the Tonghuashun Fruit Index at 3.70%, AI mobile phones at 2.77%, and MCU chips at 2.60%, while the high-pressure oxygen chamber concept was among the top decliners [2] - The main funds saw significant outflows from several stocks in the high-pressure oxygen chamber sector, with Innovate Medical, Aoyang Health, and Dahu Co. being the most affected [2] - Conversely, Iron Construction Heavy Industry, Samsung Medical, and Jinling Pharmaceutical attracted net inflows of main funds, indicating a shift in investor interest [2]

Core Viewpoint - Jinling Pharmaceutical's subsidiary, Fuzhou Meifeng Pharmaceutical Factory, has received a re-registration approval notice for hydrolyzed protein injection from the Fujian Provincial Drug Administration, which is expected to facilitate the resumption of production and sales of the drug [1] Group 1: Company Developments - The drug approval notification number is 2025R079210, and the product specification is 500ml:25g (hydrolyzed protein), classified as a chemical drug [1] - The hydrolyzed protein injection is indicated for severe amino acid deficiency and hypoproteinemia [1] - Due to long-term suspension of production, the company must apply for an on-site inspection from the provincial drug administration before resuming production and sales [1] Group 2: Market Impact - The re-registration is beneficial for the drug's production and sales recovery, but it is noted that there will be no significant impact on the company's recent performance [1] - The production and sales of the drug are subject to uncertainties influenced by policies and market factors [1]